Matthew Viscito, MD
Family Medicine · Grafton, NDNPI 1497969570
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $325 and has fallen 51.1% since, to $159 in 2025.
Across 81 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$231
- Boehringer Ingelheim$145
- AbbVie$142
- Novartis$137
- Merck$72
- Pfizer$64
- plus $504 from 16 others
What the payments were for
- Food & beverage$1,295100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $231 |
| Boehringer Ingelheim | 8 | $145 |
| AbbVie | 9 | $142 |
| Novartis | 8 | $137 |
| Merck | 4 | $72 |
| Pfizer | 4 | $64 |
| Mylan Specialty L.p. | 4 | $64 |
| Sanofi-aventis U.S. LLC | 5 | $63 |
| Amgen | 4 | $61 |
| Lilly USA, LLC | 4 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Boston Scientific | 1 | $26 |
| Johnson & Johnson | 1 | $23 |
| Philips North America LLC | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Viatris Specialty LLC | 1 | $16 |
| Smith+Nephew | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Electromed, Inc. | 1 | $16 |
| Hologic Inc | 2 | $14 |
How this compares
$1,295 in reported general payments places this provider in the 85th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $77,567 |
| OzempicSemaglutide | 44 | $61,322 |
| XareltoRivaroxaban | 56 | $39,495 |
| RybelsusSemaglutide | 11 | $17,693 |
| Bydureon BciseExenatide Microspheres | 15 | $17,004 |
| JardianceEmpagliflozin | 22 | $16,750 |
| TrulicityDulaglutide | 16 | $15,017 |
| FarxigaDapagliflozin Propanediol | 24 | $14,114 |
| MyrbetriqMirabegron | 28 | $11,911 |
| Spiriva RespimatTiotropium Bromide | 16 | $11,240 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $9,950 |
| JanuviaSitagliptin Phosphate | 13 | $7,874 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $7,431 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $6,295 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $5,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $231 | $79,01555 claims |
| PfizerEliquis | $64 | $77,567140 claims |
| Johnson & JohnsonXarelto | $23 | $39,49556 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $145 | $27,98938 claims |
| Lilly USA, LLCTrulicity | $56 | $15,01716 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $11,91128 claims |
| MerckJanuvia | $72 | $7,87413 claims |
| NovartisEntresto | $137 | $4,06520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Grafton
- Jennifer ShawGrafton$2K
- Sheila TrontvetGrafton$1K
- Richard VetterWest Fargo$294K
- Thomas ThorsonMandan$241K
- Gregory GreekGrand Forks$216K
- Katherine NeubauerWest Fargo$160K
- Spencer BerryFargo$81K
- Eric JohnsonGrand Forks$52K
- Stuart TopleyFargo$24K
- Jacqueline QuisnoBismarck$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.